These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 21549858)
1. The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus. Jin N; Wang Q; Zhang X; Jiang D; Cheng H; Zhu K Int Immunopharmacol; 2011 Sep; 11(9):1319-26. PubMed ID: 21549858 [TBL] [Abstract][Full Text] [Related]
2. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. Iwata Y; Wada T; Furuichi K; Sakai N; Matsushima K; Yokoyama H; Kobayashi K J Am Soc Nephrol; 2003 Jan; 14(1):57-67. PubMed ID: 12506138 [TBL] [Abstract][Full Text] [Related]
4. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice. Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682 [TBL] [Abstract][Full Text] [Related]
5. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF). Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004 [TBL] [Abstract][Full Text] [Related]
6. Dry eye management in a Sjögren's syndrome mouse model by inhibition of p38-MAPK pathway. Ma X; Zou J; He L; Zhang Y Diagn Pathol; 2014 Jan; 9():5. PubMed ID: 24443980 [TBL] [Abstract][Full Text] [Related]
7. Activation of farnesoid X receptor attenuates liver injury in systemic lupus erythematosus. Lian F; Wang Y; Chen J; Xu H; Yang X; Liang L; Zhan Z; Ye Y; Chen M Rheumatol Int; 2012 Jun; 32(6):1705-10. PubMed ID: 21431940 [TBL] [Abstract][Full Text] [Related]
8. Alteration in kidney glucose and amino acids are implicated in renal pathology in MRL/lpr mice. Alexander JJ; Zwingmann C; Jacob A; Quigg R Biochim Biophys Acta; 2007 Oct; 1772(10):1143-9. PubMed ID: 17942282 [TBL] [Abstract][Full Text] [Related]
9. Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Francescato HD; Costa RS; Silva CG; Coimbra TM Life Sci; 2009 Apr; 84(17-18):590-7. PubMed ID: 26324989 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of p38 mitogen-activated protein kinase attenuates experimental autoimmune hepatitis: involvement of nuclear factor kappa B. Ma X; Jia YT; Qiu DK World J Gastroenterol; 2007 Aug; 13(31):4249-54. PubMed ID: 17696256 [TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis. Zhi-Chun L; Qiao-Ling Z; Zhi-Qin L; Xiao-Zhao L; Xiao-xia Z; Rong T Inflammation; 2012 Jun; 35(3):935-43. PubMed ID: 22009442 [TBL] [Abstract][Full Text] [Related]
12. [Protection of Rho-associated protein kinase inhibitor Y-27632 in MRL/lpr mice]. Wang Y; Jia X; Wang Q; Ye M; Lu Y; Zhang J; Chen S; Li Y; Wu J; Xie C Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jul; 33(7):875-880. PubMed ID: 28712392 [TBL] [Abstract][Full Text] [Related]
13. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model. Sugiyama N; Kohno M; Yokoyama T Nephrol Dial Transplant; 2012 Apr; 27(4):1351-8. PubMed ID: 22076433 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of PI3Kδ improves systemic lupus in mice. Wang Y; Zhang L; Wei P; Zhang H; Liu C Inflammation; 2014 Jun; 37(3):978-83. PubMed ID: 24445960 [TBL] [Abstract][Full Text] [Related]
16. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Elliott MK; Jarmi T; Ruiz P; Xu Y; Holers VM; Gilkeson GS Kidney Int; 2004 Jan; 65(1):129-38. PubMed ID: 14675043 [TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP catabolism up-regulation in MRL/lpr lupus-prone mice is associated with organ remodeling. Yougbaré I; Keravis T; Abusnina A; Decossas M; Schall N; Muller S; Lugnier C Biochim Biophys Acta; 2014 Jul; 1842(7):916-26. PubMed ID: 24631654 [TBL] [Abstract][Full Text] [Related]
18. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. Atkinson C; Qiao F; Song H; Gilkeson GS; Tomlinson S J Immunol; 2008 Jan; 180(2):1231-8. PubMed ID: 18178863 [TBL] [Abstract][Full Text] [Related]
19. Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist. Itto R; Oe Y; Imaruoka K; Sato E; Sekimoto A; Yamakage S; Kumakura S; Sato H; Ito S; Takahashi N Tohoku J Exp Med; 2019 Oct; 249(2):127-133. PubMed ID: 31666446 [TBL] [Abstract][Full Text] [Related]
20. SB203580, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis by down-regulating proinflammatory cytokines and proteolytic factors in a mouse model. Zhou WD; Yang HM; Wang Q; Su DY; Liu FA; Zhao M; Chen QH; Chen QX Hum Reprod; 2010 Dec; 25(12):3110-6. PubMed ID: 20956267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]